ArticleFrontiers in surgery2026
The lung cancer pathway: seven years of evaluation of multidisciplinary pre-operative management and workflow optimization.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multidisciplinary management is essential in thoracic oncology to optimize diagnostic assessment, treatment planning, and patient selection for surgery. Structured clinical pathways may improve coordination among specialists and reduce delays in the management of patients with suspected or confirmed lung cancer. Methods: We retrospectively analyzed patients managed within a structured Lung Cancer Pathway (LCP) at Fondazione Policlinico Universitario A. Gemelli IRCCS between January 2018 and December 2024. All patients entering the LCP were included, regardless of final treatment allocation. The pathway involved multidisciplinary assessment including thoracic surgeons, pulmonologists, oncologists, radiologists, pathologists, nuclear medicine specialists, and interventional specialists. The primary endpoints were: -time from LCP initiation to clinical record closure;-time from clinical record closure to surgical intervention.Workflow times were analyzed using median values and interquartile ranges (IQR). Differences between 2018 and 2024 were assessed using the Mann-Whitney U test, while temporal trends across the study period were evaluated using the Kruskal-Wallis test. Results: A total of 2,691 patients were included. During the study period, the annual number of patients increased progressively, reflecting the expansion of the pathway. The median duration of the LCP significantly decreased from 9 days (IQR 2-23) in 2018 to 1 day (IQR 0-8) in 2024 ( Conclusions: A structured Lung Cancer Pathway was associated with improved efficiency of the diagnostic and decision-making process over a seven-year period. The LCP model allowed standardized evaluation of patients with suspected or confirmed lung cancer, including those ultimately considered unsuitable for surgery. Although the retrospective design does not allow causal inference, these findings support the potential value of structured multidisciplinary pathways in optimizing workflow organization and clinical decision-making in thoracic oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.